Company intelligence / Profile preview

LOK Enterprises

Ownership: Private
Development stage: Other

Overview

Lokon Pharma is a Swedish biotech company developing tumor microenvironment-targeted gene therapies using engineered oncolytic adenoviruses. Their lead program, LOAd703, has received orphan drug designation from both EMA and FDA for pancreatic cancer. Clinical data have been presented at major conferences such as ASCO and AACR, including studies of LOAd703 alone or in combination with chemotherapy or atezolizumab in melanoma and pancreatic cancer. The company collaborates with Roche on several clinical programs.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapyBiologic
Industry: Biotech

Partnerships

Roche

Beyond the preview

Go deeper on LOK Enterprises.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LOK Enterprises.

Explore the full profile